Daily Management Review

Teva to Buy Auspex Pharmaceuticals


03/30/2015


Israel's Teva Pharmaceutical Industries company announced the purchase of American Auspex Pharmaceuticals for $ 3.2 billion on Monday. The deal, approved by the boards of directors of both companies and major shareholders of Auspex, is scheduled for completion in mid-2015.



According to Teva’s report, the company will pay $ 101 per share of Auspex to expand its portfolio of products for the treatment of diseases affecting the musculoskeletal system.

Share price proposed by Teva is 42% higher than Auspex quote, which at the close of trading in New York on Friday was $ 70.91, reports Interfax.

According to forecasts of Teva, the deal will slightly reduce the adjusted earnings per share in 2015-2016 years, but will positively affect revenues starting next year, and will have a positive impact from 2017.

Teva’s shares fell 0.3% in the primary auction in New York on Monday.

Auspex Pharmaceuticals is a biopharmaceutical company specialized in the development of the drugs production to combat diseases associated with disorders of the nervous system.

At the end of 2014, Auspex Pharmaceuticals presented convincing results of clinical trials of experimental drugs SD-809, created for the treatment of Huntington's disease associated with chorea. The effectiveness of drugs was assessed by changes in the intensity of manifestation of chorea according to Unified Huntington`s Disease Rating Scale. Scientists have noted that the intake of SD-809 improved condition of the patients by 4.4 points on the scale, whereas the figure was 1.9 points in the placebo group. In general, the new drug was well tolerated.

In fourth quarter 2014, net income amounted to 687 million dollars against $ 380 million for the reporting period of 2013, the financial report says.

Quarterly sales fell from $ 5.4 billion to 5.2 billion dollars, as it was predicted by analysts.

Sales of generic drugs in the IV quarter declined overall by 8% - to $ 2.5 billion, by 16% in Europe. Sales of the multiple sclerosis treatment Copaxone decreased by 2% - to $ 1.1 billion.

For the entire 2014, sales of Teva remained at 2013 and was 20.3 billion dollars.

Net income increased to $ 3.1 billion, compared to $ 1.3 billion in 2013.
 
Auspex Pharmaceuticals Inc. is US biopharmaceutical company founded in 2001. Auspex specializes in the creation and commercialization of drugs for the treatment of rare (orphan) diseases. The number of employees is approximately 30 people.

source: Wall Street Journal.com






Science & Technology

Designing Of Cars Being Done With Hologram Goggles At Ford

The Already Surging Cyber Attacks Are Set To Rise Even Further, Says A Study

Chinese to equip smartphones with OLED displays

Based On One Photo, Research Shows A.I. Can Detect The Sexual Orientation Of A Person

Cyber Crime Risks Are Substantial, Systemic, Says SEC Chief

Tech Titans, Amazon & Microsoft, Partner To Integrate Their Respective A.I. ‘Voice Assistants’

SpaceX Selects Technical University Team’s Hyperloop As The Winner Of The ‘Fast Pod’

Market of autonomous cars will accelerate by 2025

AHA Customers In Iceland Enjoy The First ‘Drone Delivery Service’ In The World

Wal-Mart to unite with Google's voice platform

World Politics

World & Politics

Strong 3.4 magnitude earthquake detected coming from North Korea’s nuclear test site

Even As Kim And Trump Trade Threats, South Korea Approves $8 Million Aid For The North

From October 1 Uber is banned in London

Concerns about the far-right party are growing in Germany

Fight for clean air: 7 countries against internal combustion engines

Japan, India Agree To Deepen Defence With China In Mind

Myanmar's Rohingya Crisis May Be Taken Advantage Of By Terror Groups

The French people voted for Labour Reforms, there is no turning back: French Prime Minister Edouard Philippe